Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Prexasertib mesylate monohydrate by Acrivon Therapeutics for Refractory Medulloblastoma: Likelihood of Approval
Prexasertib mesylate monohydrate is under clinical development by Acrivon Therapeutics and currently in Phase I for Refractory Medulloblastoma. According to...
Prexasertib mesylate monohydrate by Acrivon Therapeutics for Oral Cavity (Mouth) Cancer: Likelihood of Approval
Prexasertib mesylate monohydrate is under clinical development by Acrivon Therapeutics and currently in Phase II for Oral Cavity (Mouth) Cancer....
Prexasertib mesylate monohydrate by Acrivon Therapeutics for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
Prexasertib mesylate monohydrate is under clinical development by Acrivon Therapeutics and currently in Phase II for Head And Neck Squamous...
Prexasertib mesylate monohydrate by Acrivon Therapeutics for Hypopharyngeal Cancer: Likelihood of Approval
Prexasertib mesylate monohydrate is under clinical development by Acrivon Therapeutics and currently in Phase II for Hypopharyngeal Cancer. According to...
Prexasertib mesylate monohydrate by Acrivon Therapeutics for Laryngeal Cancer: Likelihood of Approval
Prexasertib mesylate monohydrate is under clinical development by Acrivon Therapeutics and currently in Phase II for Laryngeal Cancer. According to...
Prexasertib mesylate monohydrate by Acrivon Therapeutics for Oropharyngeal Cancer: Likelihood of Approval
Prexasertib mesylate monohydrate is under clinical development by Acrivon Therapeutics and currently in Phase II for Oropharyngeal Cancer. According to...
Prexasertib mesylate monohydrate by Acrivon Therapeutics for Recurrent Medulloblastoma: Likelihood of Approval
Prexasertib mesylate monohydrate is under clinical development by Acrivon Therapeutics and currently in Phase I for Recurrent Medulloblastoma. According to...